GSK to license Hutchmed’s KRAS-EGFR cancer drug for $110M upfront

GSK will spend $110 million upfront for a license to a KRAS-EGFR antibody conjugate developed by Hutchmed, with up to $1.185 billion in biobucks on the line. The Chinese biopharma said ...